Revenue Recognition (Tables)

9 Months Ended

Sep. 30, 2018

Revenue Recognition

Schedule of disaggregation of revenue by test families

	Three months ended				Nine months ended
	September 30,				September 30,
	2018		2017		2018		2017
(Amounts in thousands)			(As Revised)				(As Revised)
Sales of genetic tests
Panorama NIPT	$	35,999	$	33,889	$	104,981	$	97,975
HCS		23,565		17,900		63,248		47,325
Other genetic tests		3,098		2,723		9,055		8,535
Product revenues		62,662		54,512		177,284		153,835
Licensing and other
Constellation		1,054		1,058		3,652		3,091
Other		1,564		340		9,753		649
Licensing and other revenues		2,618		1,398		13,405		3,740
Total revenues	$	65,280	$	55,910	$	190,689	$	157,575

Schedule of disaggregation of revenue by sales vertical

	Three months ended				Nine months ended
	September 30,				September 30,
	2018		2017		2018		2017
(Amounts in thousands)			(As Revised)				(As Revised)
Insurance carriers	$	50,631	$	44,410	$	143,094	$	124,272
Laboratory partners		9,162		9,286		34,182		26,558
Patients		5,487		2,214		13,413		6,745
Total revenues	$	65,280	$	55,910	$	190,689	$	157,575

Schedule of total revenue by geographic area

	Three months ended				Nine months ended
	September 30,				September 30,
	2018		2017		2018		2017
(Amounts in thousands)			(As Revised)				(As Revised)
United States	$	58,651	$	49,896	$	165,646	$	139,728
Americas, excluding U.S.		932		773		2,629		2,258
Europe, Middle East, India, Africa		3,711		3,443		16,789		10,279
Other		1,986		1,798		5,625		5,310
Total revenues	$	65,280	$	55,910	$	190,689	$	157,575

Schedule of changes in the balances of the Company's contract assets and liabilities

	Balance at		Balance at
	September 30,		December 31,
	2018		2017
(Amounts in thousands)			(As Revised)
Assets:
Accounts receivable	$	60,397	$	44,089
Liabilities:
Deferred revenue, current portion	$	1,156	$	1,420
Deferred revenue, long-term portion		36,850		—
Total deferred revenues	$	38,006	$	1,420

Schedule of changes in the balance of deferred revenues

	Deferred
	Revenues
	(in thousands)
Balance at December 31, 2017	$	1,420
Increase in deferred revenues		38,082
Revenue recognized during the period that was included in deferred revenues at the beginning of the period		(700)
Revenue recognized from performance obligations satisfied within the same period		(796)
Balance at September 30, 2018	$	38,006